Gabriele Cerrone Purchases 5,000 Shares of Tiziana Life Sciences PLC (TILS) Stock
Tiziana Life Sciences PLC (LON:TILS) insider Gabriele Cerrone acquired 5,000 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were purchased at an average price of GBX 112 ($1.46) per share, with a total value of £5,600 ($7,294.52).
Gabriele Cerrone also recently made the following trade(s):
- On Monday, September 10th, Gabriele Cerrone acquired 2,000 shares of Tiziana Life Sciences stock. The shares were purchased at an average price of GBX 105 ($1.37) per share, with a total value of £2,100 ($2,735.44).
- On Thursday, August 23rd, Gabriele Cerrone acquired 5,000 shares of Tiziana Life Sciences stock. The shares were purchased at an average price of GBX 111 ($1.45) per share, with a total value of £5,550 ($7,229.39).
- On Thursday, August 16th, Gabriele Cerrone acquired 412,914 shares of Tiziana Life Sciences stock. The shares were purchased at an average price of GBX 45 ($0.59) per share, with a total value of £185,811.30 ($242,036.34).
LON:TILS opened at GBX 109.50 ($1.43) on Friday. Tiziana Life Sciences PLC has a 12 month low of GBX 91 ($1.19) and a 12 month high of GBX 240 ($3.13).
Tiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
Featured Story: Understanding Analyst Recommendations
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.